Weekly Roundup: October 12-16

October 16, 2020

ICYMI, some of the content featured this week includes new 730 nm picosecond laser for benign pigmented lesions, managing patient volumes during the COVID-19 pandemic, tips on how to build your brand as a physician, plus more.

In case you missed it, some of this week’s featured content includes tips on how to build your brand as a physician, a new 730 nm picosecond laser for benign pigmented lesions, managing patient volumes during the COVID-19 pandemic, why retinoids can be found in many anti-aging formulations, different professional standards of disclosure, female surgeon representation within Mohs micrographic surgery in the U.S., plus more.

POLL: Is climate change a rising issue within dermatology?

What’s new on Dermatology Times: October 12-16

A glimpse at what to expect from Dermatology Times this week.

The Mainstream Patient: October 12

This week’s edition of The Mainstream Patient features stories about a new toxic-free cosmetics bill in California, the benefits of benzoyl peroxide for acne, the legitimacy of collagen supplements, potential sunscreen changes by the FDA, plus more.

Importance of building your brand as a physician

In this video interview, Paige Velasquez Budde, CEO of Zilker Media, explains the importance of building and shaping your brand as a physician.

What happened at ASDS?

Catch up on all of the latest news coming out of the 2020 American Society for Dermatologic Surgery (ASDS) virtual meeting.

730 nm picosecond laser safe, effective for benign pigmented lesions

Lasers typically used for tattoo removal are on the rise as a possible treatment for melasma, with the novel 730 nm picosecond laser (PicoWay, Candela) being the most recently studied device which showed to be safe and effective for treating benign pigmented lesions.

Shaping your brand awareness

In part two of this video series, Paige Velasquez Budde, CEO of Zilker Media, reveals the benefits of shaping your brand awareness.

Cysteamine cream, tranexamic acid mesotherapy reveal similar efficacy, different safety

Cysteamine cream and tranexamic acid mesotherapy demonstrated similar efficacy but yielded different safety results when being compared as a treatment for melasma, according to a recently published study.

I warned my patient – was it enough?

In this month’s Legal Eagle article, David J. Goldberg, M.D., J.D., discusses the different professional standards of disclosure that a physician must fulfill when treating patients.

Tips for building your brand

In the final installment of this video series, Paige Velasquez Budde, CEO of Zilker Media, provides some useful tips for jump starting your brand as a physician.

Managing pandemic patient volumes

Since the start of the pandemic, dermatologists have seen an average 50% drop in patient volume. While teledermatology has offered a channel for non-urgent patients and patient visits are rebounding, overall patient volumes are still significantly lower than 2019.

The retinoid revolution 

Zoe Diana Draelos, M.D., shares why retinoids can be found in many anti-aging formulations and how to reduce irritation from this potent antioxidant.

Misinformation delays rosacea diagnosis in skin of color patients

The idea that rosacea is uncommon in darker skinned individuals may be due to under-recognition. Careful clinical examination, a thorough history and biopsy in some cases are needed for accurate diagnosis and differentiating rosacea from diseases that may be more common.

Phenotype-based approach advances management

The 21-member global ROSacea Consensus panel developed updated recommendations for rosacea, diagnosis, classification and management to support and promote transition to a phenotype approach in rosacea.